GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (NAS:FLGT) » Definitions » Net Income (Continuing Operations)

Fulgent Genetics (Fulgent Genetics) Net Income (Continuing Operations) : $-175.2 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Fulgent Genetics Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Fulgent Genetics's Net Income (Continuing Operations) for the three months ended in Dec. 2023 was $-134.3 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was $-175.2 Mil.


Fulgent Genetics Net Income (Continuing Operations) Historical Data

The historical data trend for Fulgent Genetics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Net Income (Continuing Operations) Chart

Fulgent Genetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.41 214.31 506.24 141.92 -175.24

Fulgent Genetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.08 -15.85 -11.59 -13.47 -134.33

Fulgent Genetics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-175.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fulgent Genetics  (NAS:FLGT) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Fulgent Genetics Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Fulgent Genetics (Fulgent Genetics) Business Description

Traded in Other Exchanges
Address
4978 Santa Anita Avenue, Temple City, CA, USA, 91780
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Executives
Jian Xie officer: Chief Operating Officer C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVE, EL MONTE CA 91731
Hanlin Gao 10 percent owner, officer: Chief Scientific Officer 4399 SANTA ANITA AVE., EL MONTE CA 91731
Paul Kim officer: CFO and Treasurer 4399 SANTA ANITA AVE, EL MONTE CA 91731
Regina E Groves director 5751 COPLEY DRIVE, SAN DIEGO CA 92111
Leonard E Post director
Michael Nohaile director C/O BIO AI ACCELERATION COMPANY, 20 UNIVERSITY AVENUE, CAMBRIDGE MA 02138
John C Bolger director 4978 SANTA ANITA AVENUE, SUITE 205, TEMPLE CITY CA 91780
Ming Hsieh Trust 10 percent owner 4399 SANTA ANITA AVE., EL MONTE CA 91731
Linda Marsh director 100 N. STONEMAN AVE., ROOM 200, ALHAMBRA CA 91801
Ming Hsieh director, 10 percent owner, officer: President and CEO 4399 SANTA ANITA AVE., EL MONTE CA 91731
Fulgent Genetics, Inc. director 4399 SANTA ANITA AVE, EL MONTE CA 91731
Yun Yen director 1301 OAKLAWN ROAD, ARCADIA CA 91006
James Mulay director 6521 THOROUGHBRED LOOP, ODESSA FL 33556
Xi Long Usa, Inc. 10 percent owner #6 XINRUI RD., SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY F4 510663

Fulgent Genetics (Fulgent Genetics) Headlines

From GuruFocus

This Insider Just Sold Shares of Fulgent Genetics Inc

By GuruFocus Research GuruFocus Editor 05-21-2023

Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel

By Business Wire Business Wire 02-28-2023